Published in Circulation on October 01, 1979
One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed) (1982) 2.39
Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut (1985) 1.07
Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol (2010) 1.03
Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in DeltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome. Acta Physiol (Oxf) (2007) 0.99
Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest (1990) 0.90
Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. Cardiovasc Res (2009) 0.87
Antiarrhythmic therapy with flecainide in combination and comparison with propranolol. Drugs (1985) 0.79
A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics. J Gen Physiol (2015) 0.78
Beta adrenergic receptor blockade of feline myocardium. Cardiac mechanics, energetics, and beta adrenoceptor regulation. J Clin Invest (1986) 0.77
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
What clinical information do doctors need? BMJ (1996) 16.23
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Informed consent: the intricacies. BMJ (1997) 13.97
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
The failings of NICE. BMJ (2000) 8.50
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Rationing: the search for sunlight. BMJ (1992) 5.26
Publishing information about patients. BMJ (1995) 5.19
The future of healthcare systems. BMJ (1997) 5.14
Prejudice against doctors and students from ethnic minorities. Br Med J (Clin Res Ed) (1987) 5.12
The war on drugs. BMJ (1996) 5.11
Global information flow. BMJ (2000) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med (1997) 4.98
Where is the wisdom...? BMJ (1991) 4.85
Medicine and the marginalised. They deserve the best, not the poorest, care. BMJ (2000) 4.80
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Time to register randomised trials. The case is now unanswerable. BMJ (1999) 4.55
PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS. BMJ (1999) 4.54
Moving beyond journals: the future arrives with a crash. BMJ (1999) 4.49
Rationing: the debate we have to have. BMJ (1995) 4.47
Time to redefine authorship. BMJ (1996) 4.39
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Animal research: the need for a middle ground. BMJ (2001) 4.34
Conflict of interest and the BMJ. BMJ (1994) 4.34
Prison medicine: beginning again. BMJ (1992) 4.29
Measuring the social impact of research. BMJ (2001) 4.17
The case for structuring the discussion of scientific papers. BMJ (1999) 4.16
Peer review: reform or revolution? BMJ (1997) 4.13
Profile of the GMC: The day of judgment comes closer. BMJ (1989) 4.10
Managing the clinical performance of doctors. A coherent response to an intractable problem. BMJ (1999) 4.08
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J (1970) 3.80
Protein kinase activity associated with polyoma virus middle T antigen in vitro. Cell (1979) 3.78
Profile of the GMC. 1978 and all that. BMJ (1989) 3.76
"Taken from this place and hanged by the neck...". BMJ (1991) 3.72
The rights of patients in research. BMJ (1995) 3.68
All doctors are problem doctors. BMJ (1997) 3.67
The BMJ's website scales up. BMJ (1998) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
How best to organise acute hospital services? BMJ (2001) 3.63
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Netprints: the next phase in the evolution of biomedical publishing. BMJ (1999) 3.60
GMC: approaching the abyss. BMJ (2001) 3.52
The deliberate misdiagnosis of major depression in primary care. Arch Fam Med (1994) 3.46
Pleasing both authors and readers. A combination of short print articles and longer electronic ones may help us do this. BMJ (1999) 3.44
New government, same narrow vision. BMJ (1998) 3.40
Don't treat shackled patients. BMJ (1997) 3.40
The woolwich and erith project. Planning a community health service. Lancet (1966) 3.34
Almost no evidence exists that the internet harms health. BMJ (2001) 3.31
Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell (1979) 3.26
Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24
The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun (1976) 3.22
Opening up BMJ peer review. BMJ (1999) 3.21
Doctors, unethical treatments, and turning a blind eye. BMJ (1989) 3.13
Urinary prostaglandins. Identification and origin. J Clin Invest (1975) 3.07
Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst (1999) 3.07
Reconfiguring acute hospital services. No easy answers, but there are principles we should follow. BMJ (1999) 3.07
Authorship is dying: long live contributorship. BMJ (1997) 3.07
Hamster health care. BMJ (2001) 3.06
Promoting research into peer review. BMJ (1994) 3.05
Rationing health care: moving the debate forward. BMJ (1996) 3.03
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
GMC in the dock again. BMJ (1993) 2.99
Maintaining the integrity of the scientific record. BMJ (2001) 2.98
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther (2009) 2.98
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther (2009) 2.96
Altered relation of two collagen types in osteogenesis imperfecta. N Engl J Med (1977) 2.93
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science (1988) 2.93
DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry (2004) 2.91